FBIO
Fortress Biotech, Inc.
$2.85
+7.55%
$97.3M
No data for this timeframe.
Vol
Market Cap$97.3M
Cap SizeMicro Cap
Inst. Holders6 funds
Inst. Value$4.9M
Inst. Activity2 buys / 1 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Recent Activity
May 19, 2026
other
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation
May 18, 2026
SEC
Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare Conference. The filing is
PRESS-RELEASE — Impact 2/10
May 4, 2026
SEC
Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty Conference. No financial
PRESS-RELEASE — Impact 2/10
Apr 1, 2026
Insider
Jin David sold 2,967 shares
Chief Financial Officer @ $2.18 ($6.5K)
Mar 18, 2026
Insider
ROSENWALD LINDSAY A MD sold 475,424 shares
PRESIDENT, CEO & CHAIRMAN @ $0.00 ($0.00)
Mar 18, 2026
Insider
WEISS MICHAEL S sold 475,424 shares
Executive Vice Chairman @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
139,151 shares ($509.3K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
81,100 shares ($296.8K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$11.00 (Feb 2026)
Current $2.93
Low $5.00
Median $11.00
High $17.00
2 analysts
$5.00
$17.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▼ -5.3% | $-0.20 — $-0.20 | -144% YoY | 1 |
| Next Q | $-0.15 ▲ +6.3% | $-0.15 — $-0.15 | -236% YoY | 1 |
| Current FY | $2.40 ▲ +442.9% | $2.40 — $2.40 | 3529% YoY | 1 |
| Next FY | $0.51 | $-0.50 — $1.51 | -79% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
2/10
Fortress Biotech announced CEO participation in a fireside chat at A.G.P.'s Virtual Healthcare Conference. The filing is
May 18, 2026
NEUTRAL
PRESS-RELEASE
2/10
Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty Conference. No financial
May 4, 2026
BULLISH
Press
8/10
Fortress Biotech announced the closing of the $205 million sale of a Rare Pediatric Disease Priority Review Voucher (PRV
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.0M | — |
| TWO SIGMA INVESTMENTS, LP | $509.3K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $296.8K | ADD |
| WELLS FARGO & COMPANY/MN | $18.3K | NEW |
| MORGAN STANLEY | $7.9K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Jin David | A | $6.5K |
| Mar 18, 2026 | ROSENWALD LINDSAY | A | $0.00 |
| Mar 18, 2026 | WEISS MICHAEL | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $4.9M total value (1,328,438 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,100,570 | $4.0M | 82.8% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 139,151 | $509.3K | 10.5% | ADD +63.7% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 81,100 | $296.8K | 6.1% | ADD +98.8% |
| 4 | WELLS FARGO & COMPANY/MN | 5,000 | $18.3K | 0.4% | NEW |
| 5 | MORGAN STANLEY | 2,158 | $7.9K | 0.2% | NEAR_EXIT -78.3% |
| 6 | BANK OF AMERICA CORP /DE/ | 459 | $1.7K | 0.0% | NEAR_EXIT -93.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 84,981 | 139,151 | +63.7% | $509.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 40,800 | 81,100 | +98.8% | $296.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 7,122 | 459 | -93.6% | $1.7K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 45,832 | 84,981 | +85.4% | $314.0K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 40,800 | — | $150.8K | 2025-Q3 |
| UBS Group AG | TRIM | 43,155 | 30,290 | -29.8% | $111.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 696 | 7,122 | +923.3% | $26.3K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEW | — | 5,000 | — | $18.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 12,659 | 43,155 | +240.9% | $80.3K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 11,338 | 2,457 | -78.3% | $4.6K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 32,000 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 284,861 | 79,793 | -72.0% | $124.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 175,800 | 32,000 | -81.8% | $49.9K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 2,457 | 11,338 | +361.5% | $17.7K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 20,749 | 1,950 | -90.6% | $3.0K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 9,006 | 16 | -99.8% | $25.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 46,963 | 284,861 | +506.6% | $576.8K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 78,088 | 175,800 | +125.1% | $356.0K | 2024-Q4 |
| UBS Group AG | NEW | — | 11,821 | — | $23.9K | 2024-Q4 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Jin David | Chief Financial Officer | A | 2,967 | $2.18 | $6.5K |
| Mar 18, 2026 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | A | 475,424 | $0.00 | $0.00 |
| Mar 18, 2026 | WEISS MICHAEL S | Executive Vice Chairman | A | 475,424 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.0/10.
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$11.00 mean target (Feb 2026)
$5.00 Low
$17.00 High
| Metric | Value |
|---|---|
| Current Price | $2.93 |
| Target Low | $5.00 |
| Target Mean | $11.00 |
| Target Median | $11.00 |
| Target High | $17.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.20 | $-0.20 | -144.4% | -5.3% | 0↑ 1↓ | $0.0B | 11.5% | 1 |
| Next Q 2026-09-30 |
$-0.15 | $-0.15 | $-0.15 | -236.4% | +6.3% | 1↑ 0↓ | $0.0B | 26.4% | 1 |
| Current FY 2026-12-31 |
$2.40 | $2.40 | $2.40 | 3528.6% | +442.9% | — | $0.1B | 26.3% | 1 |
| Next FY 2027-12-31 |
$0.51 | $-0.50 | $1.51 | -79.0% | +0.0% | — | $0.1B | 68.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.200 | |
| 7d ago | $-0.190 | -0.010 |
| 30d ago | $-0.190 | -0.010 |
| 60d ago | $0.000 | -0.200 |
| 90d ago | $0.000 | -0.200 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Two Pharma Plays (FBIO & BCTX)
▲ 1
💬 0
⚡ 0.5
May 19, 2026
other
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,”
May 18, 2026
earnings
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
<p align="justify">MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical compa
May 14, 2026
earnings
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="center"><em>ZYCUBO<sup>®</sup> approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed
May 13, 2026
earnings
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p>
May 13, 2026
earnings_calendar
FBIO Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
earnings
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET <pre>Company to host confe
May 4, 2026
earnings
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
<p align="justify">MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical compa
Apr 21, 2026
contract
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 <pre>Payer
Mar 31, 2026
earnings
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
<p align="center"><em>ZYCUBO<sup>® </sup>approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold i
Mar 30, 2026
contract
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
<p align="justify">MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, C
Mar 25, 2026
earnings
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
<p align="center"><em>Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024</em></p>
Mar 24, 2026
earnings_calendar
FBIO Q4 2025 Earnings After Market Close — 2026-03-24
Mar 18, 2026
earnings
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET <pre>Company to host con
Jan 14, 2026
fda_pdufa
PDUFA: FBIO — CUTX-101 in Menkes disease — 2026-01-14
FDA target action date 2026-01-14 for FBIO (Fortress Biotech, Inc.). Drug: CUTX-101. Indication: Menkes disease. FDA accepted resubmission of NDA for